GlassScriptPhysician profile
Arthur K Gran
NPI 1689945206
$3,042.05
in general payments reported to CMS, 2019-2025
16 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $140 · 2021: $63.75 · 2022: $222 · 2023: $847 · 2024: $734 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.92 |
| Education | $337.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.19 | 2021-2025 | |
| Astellas Pharma US INC | $539.88 | 2019-2025 | Cresemba |
| Merck Sharp & Dohme LLC | $464.27 | 2019-2025 | Zerbaxa, Dificid |
| Hydrofera LLC | $354.15 | 2023-2025 | Hydrofera Blue, Sorbact Other |
| Insmed, INC. | $268.92 | 2019-2025 | Arikayce |
| Kerecis Limited | $158.00 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Paratek Pharmaceuticals, INC. | $96.93 | 2019-2024 | Nuzyra |
| Melinta Therapeutics, LLC | $74.48 | 2019-2024 | Orbactiv, Kimyrsa, Vabomere |
| Ferring Pharmaceuticals INC. | $59.81 | 2025 | Rebyota |
| Shionogi INC | $43.47 | 2022-2024 | Fetroja |
| Solventum Corporation | $32.54 | 2024 | V.A.C. Granufoam, Prevena |
| Theratechnologies INC. | $28.78 | 2025 | Egrifta, Trogarzo |
| Viiv Healthcare Company | $27.45 | 2023 | Cabenuva |
| Allergan, INC. | $16.89 | 2020 | |
| Glaxosmithkline, LLC. | $13.15 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $12.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Gran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.